CTOs on the Move


 
Apps that work seamlessly together to create integrated, multichannel programs that empower people to take a dramatically more active role in improving health. Beyond members and patients, this is healthcare IT that helps doctors, providers, health plan administrators and medical device manufacturers. Not to mention Medicare Star Ratings.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Revel raised $17M on 11/29/2017

Similar Companies

Pennsylvania Environmental

Pennsylvania Environmental is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EcoArray

EcoArray is a Gainesville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zygote

Zygote is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adare Pharma Solutions

Adare Pharma Solutions is a global contract development and manufacturing organization (CDMO) focused on oral dosage forms for the pharmaceutical industry. The company offers integrated services that span from product development to commercial manufacturing and packaging, with a strong emphasis on small molecule pharmaceuticals. With around 800 employees and seven facilities in the United States and Europe, Adare is well-equipped to serve markets worldwide. The company specializes in technologies such as taste masking, customized release, and solubility enhancement, addressing unique formulation challenges. Adares product development services include formulation development, analytical method validation, and support for various regulatory submissions. Their manufacturing capabilities encompass a range of processes, including granulation, coating, and high potency manufacturing. Additionally, Adare operates a dedicated packaging facility that provides high-speed packaging solutions. The company serves a diverse customer base, including branded, specialty, generic, and veterinary pharmaceutical segments, and is committed to maintaining high regulatory standards across all operations.

iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.